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Abstract: We assessed the difference in the prevalence of hypertension in community surveys when
blood pressure (BP) was measured on two vs. one visits and its impact on hypertension awareness,
treatment and control proportions. A community-based BP screening programme was conducted in
public places in the Seychelles (619 adults) and BP was rechecked a few days later among untreated
participants with high BP (≥140/90 mmHg). A narrative review of the literature on this question was
also conducted. Only 64% of untreated participants with high BP still had high BP at the second
visit. The prevalence of hypertension in the whole sample decreased by 13% (from 33.8% to 29.5%)
when BP was measured on two vs. one visits. These results concurred with our findings in our
narrative review based on 10 surveys. In conclusion, the prevalence of hypertension can be markedly
overestimated in community surveys when BP is measured on two vs. one visits. The overestimation
could be addressed by measuring BP on a second visit among untreated individuals with high BP or,
possibly, by taking more readings at the first visit. These findings have relevance for clinical practice,
policy and surveillance.
Keywords: blood pressure; hypertension; screening; surveillance; prevalence
1. Introduction
Hypertension is the leading cause of the global disease burden, accounting for 10.4 million deaths
in 2017 [1] and contributing to 22.3% of the population attributable burden of cardiovascular disease [2].
The prevalence of high blood pressure (BP) ranges between 30–50% in adults in many populations
worldwide [3]. The World Health Organization (WHO) Global Action Plan for the Prevention and
Control of Noncommunicable Diseases (NCDs) includes the target to reduce by 25% the prevalence of
raised BP between 2010 and 2025 and summarizes cost-effective interventions to reduce its burden at
both population and individual levels [4].
BP tends to decrease over repeated readings within and across visits [5], owing to habituation to
BP measurements and regression to the mean. For example, a review of clinical studies found that
5–65% of persons who had high BP on one visit did not have hypertension when BP was measured
with ambulatory blood pressure monitoring (27 studies) and 4–42% did not have hypertension
when BP readings were repeated at subsequent office visits (4 studies) [6]. This stresses that
hypertension diagnosis should be based on several BP readings taken on several occasions (at least two),
as recommended by different international guidelines [7–9].
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Similarly, the prevalence of hypertension in community surveys (as opposed to the prevalence of
“high blood pressure”) can be assessed more reliably if BP is measured on several visits, as already
pointed out in 1969 [10]. A Canadian cross-sectional community survey showed that, while the number
of BP readings made at a single visit can influence prevalence estimates (e.g., when the prevalence is
based on the average of three readings or the last two of three readings), the prevalence decreased most
(by 12% and 17%) when based on BP readings measured again at two or three subsequent visits [11].
Similarly, the prevalence of hypertension decreased by as much as 48% when BP was measured on a
second visit taking place at least 2 years after the first visit in a recent Chinese study, independently of
hypertension treatment [12].
However, due to logistic difficulties and cost, BP is measured on one single visit in most community
surveys, e.g., WHO STEPS [13] or the May Measurement Month (MMM) screening programme [14].
Two reviews of population-based surveys of hypertension showed that only 4 out of 44 surveys [15]
and 1 out of 68 [16] had assessed BP on at least 2 visits, as opposed to BP measured on 1 visit only.
In this study, we assessed the difference in estimates of the prevalence of hypertension when
BP was measured on two visits vs. one visit in a community-based BP screening programme in
the Seychelles and the impact on hypertension awareness, treatment and control proportions in the
underlying population, an issue that has only rarely been examined [11]. We also conducted a narrative
review of all published papers on community surveys that had assessed the prevalence of hypertension
based on BP measurements on ≥two vs. one visits.
2. Materials and Methods
We analysed BP data of a community-based screening programme led by the Ministry of Health
in the Seychelles performed around World Hypertension Day every year. We included data from the
participants in 2018 and 2019. The screening programme took place in several public places in the main
island (Mahe, 90% of the total population of the Seychelles) between 9 a.m. and 2 p.m. The methods
used in the screening programme to measure BP were consistent with hypertension guidelines [7–9]
and with the May Measurement Month protocol [17,18].
The blood pressure screening was offered free to any volunteer adults aged 18 years or more.
Each participant was asked for their consent to use their anonymous data for research. A short-structured
questionnaire about socioeconomic indicators and lifestyle variables was administered to the
participants. Weight was measured using an electronic scale (seca 703®, seca GmbH & Co. KG,
Hamburg, Germany), height was measured using a fixed stadiometer (seca 220®, seca GmbH & Co. KG,
Hamburg, Germany), and random blood glucose was measured on capillary blood using glucometer
(Contour Plus®, Bayer Healthcare AG, Leverkusen, Germany). Overweight and obesity were defined
as a body mass index (BMI) of 25–29.9 kg/m2 and ≥30 kg/m2, respectively. Raised blood sugar
was defined as random blood glucose ≥7.8mmol/L, according to the American Diabetic Association
guidelines [19].
BP was measured on individuals comfortably seated in a chair with their left arm laying on a
table at the heart level, using a validated electronic device (Omron M6 Comfort®, Omron Healthcare
Co., Ltd., Kyoto, Japan) [20]. After a rest of ≥3 min, BP was measured 3 times at intervals of ≥1 min.
The screening programme was led and approved by the Ministry of Health. Participants were informed
about the screening procedures and asked for their written consent to use their data in aggregate form
for evaluative research.
Individuals with systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg (based on the average of
3 readings) and not taking any treatment for hypertension were invited to attend a second visit a few
days later. Participants could indicate their real name or a fake name on their appointment card in
order to keep their data anonymous while ensuring a link with the data from the first visit. The second
visit took place in a health promotion unit in the ministry of health where health workers wore civil
garments. On the second visit, BP was checked by the same nurse who had seen the participant at
the first visit, using the same measurement protocol and BP measuring device. No treatment for
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hypertension was prescribed between the visits. The distribution of mean BP and the prevalence of
raised BP were tabulated, and 95% confidence intervals were calculated.
The study was approved and conducted by the Ministry of Health of the Seychelles. BP readings
at Visit 1 (but not at Visit 2) have been included in previous papers from the May Measurement Month
global study in 2018 and 2019 [17,18].
We also performed a narrative review of all published papers or reviews examining the difference
in the prevalence of hypertension in population-based surveys when BP was measured on ≥2 vs. 1
visits among adults. We searched all full-text papers published in English and in French up to January
2020 available in PubMed, Cochrane Library and Google Scholar using the following descriptors:
“Hypertension, prevalence, repeated visits, two visits, repeated measurements, serial surveys.” We also
identified further pertinent publications from the lists of references. We included all papers that had the
following criteria: A population-based sample (community surveys); the prevalence of hypertension
was estimated based on BP readings taken on the first and second visits; BP measurement was based
on the average of ≥2 readings at each visit; the same measurement methods were used at each visit.
When a study did not report explicitly the relative difference in the prevalence of hypertension when
estimates were based on reading on ≥2 vs. 1 visits, the relative difference was estimated based on the
prevalence values indicated in the study (in the tables or figures). Studies that provided only data on
systolic BP [21,22], diastolic BP [23–26], using a single BP measurement on a particular visit, giving the
estimation of hypertension prevalence based on the sole reading on the final visit [27], having an
interval between visits exceeding 2 months [12] or were not community-based surveys [28,29] were
excluded. We also excluded the papers for which only the abstracts were available in the 3 searched
library databases [30–33]. Several studies included in the previously mentioned 3 reviews [6,15,16]
were excluded because they did not meet all of our inclusion criteria. In one instance, the results of a
potentially suitable study were published in both French [34] and English [35] in different journals and
we only included the publication in English in our review. We identified 51 studies that seemed to have
assessed hypertension prevalence in community survey based on ≥2 vs. 1 visits [6,10–12,15,16,21–65],
and 10 met our inclusion criteria (Table 6).
3. Results
A total of 620 individuals participated in our community-based screening programme (age range:
18 to 86 years). One participant was excluded because of missing data. Seventy-three participants
had systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg and were not treated for hypertension.
Among them, 50 (69%) had their BP measured on a second visit. The mean interval between the first
and second visits was 2.6 days (range: 1 to 12 days; 95% CI: 2.1–3.1).
Table 1 shows selected characteristics of the participants at the first visit according to age and
sex. There were 241 men (38.9%) and 378 women (61.1%), and 320 were aged <45 years (51.7%) and
299 were ≥45 years (48.3%). Almost all participants (96.9%) had their BP measured at least once in their
life and 86.1% had it checked within the past 12 months, with the highest proportion among women
over 45 years old (92.0%).
One-third of the participants (33.8%) had high BP (BP ≥140/90 mmHg or treatment) at the first
visit, with differences according to age (17.1% at age <45 years and 48.2% at age ≥45 among men,
and 15.2% and 55.6% among women of the same age categories). More than half of participants with
high BP were taking an antihypertensive treatment (men 52.6%; women 72.2%). In the whole sample,
22% of the participants were taking a BP-lowering treatment, particularly those aged ≥45 years (37.5%)
and women aged ≥45 years (43.3%). The prevalence of smoking was higher in men than women
(25.7% vs. 3.4%). Three-quarters of men and women were overweight or obese. More women than
men were obese (40.2% vs. 27.4%). Around 8% had diabetes (with a higher proportion in the older
than younger age groups).
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Participants (n) 129 112 241 191 187 378 320 299 619
Ever had BP checked (%) 92.2 98.2 95.0 98.4 97.9 98.1 95.9 98.0 96.9
Had a BP check in past 12 months (%) 76.7 86.6 81.3 86.4 92.0 89.2 82.5 90.0 86.1
BP ≥140/90 mmHg or treated (%) 17.1 48.2 31.5 15.2 55.6 35.2 15.9 52.8 33.8
From which % treated 40.9 57.4 52.6 51.7 77.9 72.2 47.1 70.9 65.1
Treated for hypertension (%) 7.0 27.7 16.6 7.9 43.3 25.4 7.5 37.5 22.0
Smoking (%) 31.0 19.6 25.7 4.2 2.7 3.4 15.0 9.0 12.1
Body mass index ≥25 kg/m2 (%) 73.6 76.8 75.1 67.0 83.4 75.1 69.7 80.9 75.1
Body mass index ≥30 kg/m2 (%) 24.0 31.3 27.4 34.6 46.0 40.2 30.3 40.5 35.2
Aware of having diabetes (%) 0.8 8.0 4.1 1.6 9.1 5.3 1.3 8.7 4.8
Random blood glucose ≥7.8 mmol/L (%) 6.2 11.6 8.7 4.2 10.7 7.4 5.0 11.0 7.9
Blood pressure (BP) estimates are based on the average of three readings.
Table 2 shows that mean systolic BP and mean diastolic BP decreased between the first, second and
third readings within each visit, with most of the decrease occurring between the first and second BP
readings. The difference between the first and third readings within each visit, for both systolic and
diastolic BP, was approximately 3 mmHg in each BP subgroup (i.e., participants with BP <140/90 mmHg,
participants treated, participants with BP ≥140/90 mmHg but untreated, and participants seen on
the second visit). The difference reached statistical significance in the BP categories with the largest
numbers of participants.
Table 2. Mean systolic and diastolic blood pressure on three successive blood pressure readings
according to hypertension status and different visits in the community-based screening programme.
Reading 1 Reading 2 Reading 3 Relative diff. (%)
n Mean 95%CI Mean 95%CI Mean 95%CI R3 vs. R1 95%CI
Visit 1 (n = 619)
BP <140/90, no Rx Sys 410 115.5 114, 117 112.8 112, 114 112.0 111, 113 −3.0 −5, −1
Dia 76.6 76, 77 75.3 74, 76 74.1 73, 75 −3.3 −5, −1
Treated Sys 136 133.1 130, 136 130.1 127, 133 128.5 126, 131 −3.5 −7, −0.4
Dia 86.4 84, 88 84.4 82, 86 83.7 82, 86 −3.1 −6, −0.3
BP ≥140/90, no Rx Sys 73 146.0 142, 150 142.4 139, 146 141.9 139, 145 −2.8 −7, 1
Visit 2 * (n = 50) Dia 96.3 94, 98 94.2 92, 96 92.8 91, 94 −3.6 −8, 1
BP ≥140/90 at V1,
no Rx Sys 50 144.8 141, 148 142.0 138, 146 140.1 137, 144 −3.2 −8, 2
Dia 94.5 92, 97 92.0 90, 94 90.0 87, 93 −4.8 −11, 1
BP: Blood pressure (mmHg); Sys: Systolic BP; Dia: Diastolic BP; V1: Visit 1. Rx: Treatment for HTN: Hypertension.
* Visit 2 was attended only by participants with BP ≥140/90 at Visit 1 and no treatment.
Table 3 shows the mean systolic/diastolic BP (based on the average of the 3 readings at each visit)
among the 50 participants with BP ≥140/90 mmHg and not treated who attended the second visit.
BP significantly decreased between the first and second visits by 5.6/3.3 mmHg for systolic/diastolic BP,
with a relative drop of respectively 3.5%/3.3% for systolic/diastolic BP, respectively. This decrease was
of a similar magnitude in both sexes and age groups.
Table 4 shows that 67.9% of men and 59.1% of women with BP ≥140/90 mmHg and untreated at the
first visit also had elevated BP (i.e., BP ≥140/90 mmHg) at the second visit. Inversely, around one-third
of untreated participants with elevated BP at the first visit no longer had elevated BP at the second
visit. In relative terms, the prevalence of hypertension (BP ≥140/90 mmHg or treatment) decreased by
12.6% (men 15.2%, women 11.4%) based on BP readings on two vs. one visits. This estimate assumed
the same decrease in BP between the 2 visits among the 28 participants with BP ≥140/90 mmHg and no
treatment who attended the second visit as in the 8 participants with hypertension who did not attend
the second visit.
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Table 3. Mean systolic/diastolic blood pressure on the first and second visits among participants to the
community-based screening programme who were untreated and had elevated blood pressure at the
first visit.
Visit 1 Visit 2 * Absolute dif.V2 vs. V1
Rel.
dif.
n BP 95%CI BP 95%CI 95%CI %
Men 28 Sys 147.8 143, 153 142.8 139, 147 −5.0 −11, 1 −3.0
Dia 95.5 92, 99 93.2 90, 97 −2.3 −7, 2 −2.8
Women 22 Sys 148.1 141, 155 141.6 136, 148 −6.5 −16, 3 −4.1
Dia 96.6 93, 99 90.9 88, 93 −4.7 −9, −1 −4.6
<45
years 14 Sys 143.7 136, 152 136.1 131, 141 −7.6 −17, 2 −4.9
Dia 96.1 92, 101 91.5 88, 95 −4.6 −10, 1 −4.6
≥45
years 36 Sys 149.5 145, 154 144.7 140, 149 −4.8 −11, 1 −3.0
Dia 95.3 93, 98 92.5 90, 95 −2.8 −7, 1 −2.8
Total 50 Sys 147.9 144, 152 142.3 139, 16 −5.6 −11,
−0.3 −3.5
Dia 95.5 93, 98 92.2 90, 94 −3.3 −7, −0.2 −3.3
BP: Blood pressure; Sys: Systolic BP; Dia: Diastolic BP; Rel. dif: Relative difference (%). * Visit 2 was attended only
by participants with BP ≥140/90 at Visit 1 and no treatment.
Table 4. Prevalence of hypertension in the community-based screening programme based on blood
pressure measured on two vs. one visits.
Men Women Total
Number with BP <140/90, untreated, Visit 1 165 245 410
Number treated, Visit 1 40 96 136
Number with BP ≥140/90, untreated, Visit 1 36 37 73
Number with BP ≥140/90, untreated, Visit 1 & had BP measured at Visit 2 28 22 50
Number with BP ≥140/90, untreated, Visit 1 & had BP ≥140/90 at Visit 2 19 13 32
* Expected number with BP ≥140 /90, untreated, V1 & BP ≥140/90 at V2 24.4 21.9 46.7
Proportion of participants untreated and with BP≥140/90 at Visit 1
who also had BP ≥140/90 at Visit 2 67.9 59.1 64.0
Prevalence (%) of hypertension in the whole sample based on BP
readings at Visit 1 31.5 35.2 33.8
Prevalence (%) of hypertension in the whole sample based on BP
readings at Visit 1 & Visit 2 26.7 31.2 29.5
Relative decrease in the prevalence of hypertension in the whole sample
based on BP measured on two vs. one visits (%) −15.2 −11.4 −12.6
BP: Blood pressure; hypertension: BP ≥140/90 mmHg (average of 3 readings) or treatment. Visit 2 (V2) was attended
only by untreated participants with BP ≥140/90 at Visit 1 (V1). * The differences in BP between V2 vs. V1 assume a
same relative BP change in eligible participants who attended V2 as in those who did not attend V2.
Table 5 shows the proportions of persons aware, treated and controlled among all persons with
hypertension (BP ≥140/90 mmHg or treatment) based on two vs. one visits. Since the denominator
of these proportions (i.e., the total number of persons with defined hypertension) was lower when
hypertension was assessed based on BP readings on two vs. one visits, the proportions of persons
aware, treated and controlled, in the entire sample, was higher by 14.4% (men 18.0%; women 12.8%)
when the diagnosis of hypertension was based on two vs. one visits.
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Table 5. Proportions of participants in the community-based screening programme who were aware,
treated and controlled for hypertension based on the total number of persons with hypertension was
based on blood pressure measured on two vs. one visits.
Men Women All
Number of participants 241 378 619
Number with hypertension based on BP measured at V1 76 133 209
Number with hypertension based on BP measured at V1 & V2 64 118 183
Number aware of having HBP 50 112 162
% aware from all participants with HBP, based on V1 (A) 65.8 84.2 77.5
% aware from all participants with HBP, based on V1 & V2 (B) 77.6 95.0 88.7
Relative difference (B vs. A) (%) 18.0 12.8 14.4
Number treated for hypertension 40 96 136
% treated from all participants with HBP, based on V1 (C) 52.6 72.2 65.1
% treated from all participants with HBP, based on V1 & V2 (D) 62.1 81.5 74.4
Relative difference (D vs. C) (%) 18.0 12.8 14.4
Number with BP controlled (<140/90 mmHg) 21 63 84
% controlled from all participants with HBP, based on V1 (E) 27.6 47.4 40.2
% controlled from all participants with HBP, based on V1&V2 (F) 32.6 53.5 46.0
Relative difference (F vs. E) (%) 18.0 12.8 14.4
V1: Visit 1; V2: Visit 2; BP: Blood pressure; HBP: High blood pressure. Hypertension: BP ≥140/90 mmHg (based on
average of 3 readings at each visit) or treatment. BP was measured at Visit 2 among untreated participants with
BP ≥140/90 at Visit 1.
Table 6 shows the 10 studies included in our narrative review of the difference in the prevalence
of hypertension based on ≥2 vs. 1 visits [11,35–43]. The included studies are displayed according to
the number of visits used to define hypertension. Mean BP was lower by 1.5–7.0 mmHg (systolic BP)
and 0.7–9.0 mmHg (diastolic BP) when comparing mean BP based on two vs. one visits. The decrease
in mean BP could be larger in those studies in which BP was measured on more than two visits.
The relative difference in the prevalence of hypertension when BP was measured on two vs. one visits
ranged between 12% and 39%, and the difference between the last and first visit could be larger when
BP was measured on more than two visits (up to 43%).
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Table 6. Narrative review: Characteristics and main results of the community surveys that had assessed the difference in the prevalence of hypertension based on
blood pressure measured on ≥two vs. one visits.
First Author
Nb Visits [ref]








Mean BP Rel. dif. HTN
PrevalenceFirst Visit Last Visit
2 visits
Inamo J [35] Martinique/Guadeloupe/Guyana, 2001–2002 6113 1—2—3 ≥140/90 or Rx ≥140/90, no Rx NA NA −19%
Lang T [36] France, 1997–1998 29,626 1—2—3 ≥140/90 or Rx ≥140/90, no Rx NA NA * −39%
Atallah A [37] Guadeloupe, 2007 CONSANT survey 1005 1—2—3 ≥140/90 or Rx ≥140/90, no Rx NR NR * −25%
Guadeloupe, 2001–2003 PHAPGG survey 20,420 1—2—3 ≥140/90 or Rx ≥140/90, no Rx NR NR * −32%
Modesti PA [38] Yemen, 2009 10,242 2—3 ≥140/90 or Rx All 123.0/76.9 121.5/76.2 −33%
Markovic N [39] Nigeria, 1992 804 2—3 ≥140/90 or Rx All * 120.5/75.4 * 116.9/85.0 NR
Pierce L [40] Haiti, 2012 175 1—2 ≥140/90 or Rx ≥140/90, no Rx NR NR * −20%
Figueiredo D [41] Portugal, 2001–2003 739 1—2
≥140/90 or Rx All NR NR −13%
≥140/90, no Rx All NR NR −31%
Bovet P [42] Tanzania, 1998–1999 9254 2—3 ≥160/95 All * 147.3/89.3 * 140.2/85.8 −29%
Birkett NJ [11] Canada, 1985–1986 2016 1—2—3/2—3 ≥160/90 or Rx ≥160/90 or Rx NA NA * −12%
3 visits
Lai M [43] China, 2017 1185 1—2—3 ≥140/90 or Rx All NR NR * −12%
Markovic N [39] Nigeria, 1992 804 2—3 ≥140/90 or Rx All * 120.5/75.3 * 115/73.3 * −14%
Birkett NJ [11] Canada, 1985–1986 2016 1—2—3/2—3 ≥160/90 or Rx ≥160/90 or Rx NA NA * −17%
4 visits
Bovet P [42] Tanzania, 1998–1999 9254 2–3 ≥160/95 All * 147.3/89.2 * 136/83.9 −43%
NA: Not applicable; NR: Not reported; BP: Blood pressure; HTN: Hypertension; Rx: Treatment; Rel. dif.: Relative difference; nb: Number; ref: Reference. * Difference in the prevalence of
hypertension based on ≥two vs. one visits based on prevalence figures displayed in the article.
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4. Discussion
Based on our community-based screening programme, the prevalence of hypertension was 13%
lower when BP was measured on two vs. one visits. This estimate seems conservative compared to the
results from our narrative review of 10 community surveys, where the prevalence of hypertension
decreased, in relative terms, by 12% to 43% between the last vs. first visits [11,35–43]. Despite the
difficulty of getting an accurate overall estimate of the impact measuring BP readings on one vs.
several visits on the prevalence of hypertension in populations due to the discrepancy between the
methods used in the studies (number of BP readings, intervals between visits, etc.), our narrative
review included the largest number of eligible such studies and provides the most solid evidence
on this question so far. We also found that the proportions of hypertension awareness, treatment
and control rates in the sample of participants to the screening programme were substantially larger
(by approximately 14% in our study) when hypertension (i.e., the denominator of these proportions)
was based on two vs. one visits. Our findings re-emphasize that the prevalence of hypertension in
population-based surveys can be substantially overestimated when BP is measured on ≥two vs. one
visits, and awareness, treatment and control rates (in the underlying populations) can consequently be
substantially underestimated when based on BP readings taken on ≥two vs. one visits.
As expected, BP decreased over three consecutive readings at each visit (with a difference of
approximately 3 mmHg between the first and third readings in our study), irrespective of initial
BP level and treatment status, consistent with findings in several other studies [5,38,39,42,47,66].
In addition, mean BP (based on triplicate readings at each visit) was lower at the second vs. first
visits by approximately 5 mmHg, which is consistent with findings in our review (Table 6) [38,39,42].
The BP decrease over repeated readings at a same visit and between subsequent visits is largely
attributed to habituation to BP measurement [42]. Of note, the marked systematic decrease in mean BP
over subsequent visits does not necessarily apply to other cardiovascular risk factors such as body
weight, blood cholesterol or blood glucose, as these latter risk factors do not necessarily systematically
decrease over consecutive visits. This underlies that hypertension guidelines stress that the diagnosis
of hypertension should be based on BP readings taken over several visits.
It is likely that the decrease in the prevalence of hypertension based on two vs. one visits may
differ between populations. First, this decrease is likely to differ according to the absolute mean BP
level in the underlying population. Indeed, the decrease in the prevalence of hypertension (or the
difference in mean BP level) based on two vs. one visits is likely to be proportionally larger if the
average BP in the underlying population is close to the cut-off value for elevated BP, as opposed to
populations where the mean BP would be markedly lower than 140/90 mmHg, because more persons
in the population would have their BP levels near the cut-off for hypertension in the former vs. latter
instances [47]. In our study, the prevalence of hypertension (defined in this study as BP≥ 140/90 mmHg)
and mean BP levels in the underlying population were quite high compared to some other countries
(e.g., North America) but were similar with several countries in Sub-Saharan Africa [17,18].
The decrease in the prevalence of hypertension based on BP measurements made on two vs.
one visits might also be larger if the proportions of untreated persons with elevated BP is high vs.
low, as a larger proportion of individuals in the underlying populations could possibly normalize
their BP over consecutive visits in the former situation. The proportion of treated persons was fairly
high in the Seychelles, at 22% of the whole population in our study, which is similar with a recent
population-based survey of cardiovascular risk factors in the country [67]. This implies that the
difference in the prevalence of hypertension in surveys based on two vs. one visits could be larger
in countries where only few people with hypertension are treated for hypertension. Further studies
should assess the prevalence of hypertension based on two vs. one visits in countries with different
mean BP levels and different proportions of hypertensive persons treated.
Another issue, not addressed in our study, is to clarify whether all persons treated for hypertension
actually had hypertension at the first place. It may happen that some persons are (inadequately)
given hypertension medication(s) on the basis of elevated BP taken on a single visit, whereas a certain
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proportion of them would not have had sustained hypertension if BP had been measured on ≥two
visits (i.e., false-positive hypertension cases). This situation would lead to overestimation of the
hypertension prevalence in epidemiological surveys. Further studies should assess the proportions of
false-positive cases in population-based surveys or in cohort studies in different populations using
treatment de-intensification in selected treated persons. However, this would require several follow-up
visits over several months. For example, a review of studies of hypertension treatment de-intensification
found that approximately one-quarter of patients on antihypertensive therapy were unnecessarily
treated and assessed with no relapse of hypertension after ≥two years of treatment discontinuation [68].
BP can further decrease when BP is based on ≥two visits vs. only one or two visits or, quite
similarly, if ambulatory BP monitoring or home BP monitoring (with multiple readings over an
extended period of time) is performed among patients with elevated BP and no treatment. For example,
the prevalence of hypertension decreased further when BP was measured on three vs. two visits in
two population-based surveys in Tanzania [42] and Nigeria [39].
Another issue is the impact of a white coat effect on the prevalence of hypertension in
epidemiological studies, whereby BP is artificially increased when BP is measured by medical
personnel [41,69]. This factor can increase the overestimation of the prevalence of hypertension in
epidemiological studies, but this overestimation could possibly be partially compensated by the effect
of masked hypertension on the prevalence of hypertension [69]. In this study, BP was measured in
secluded places (first visit) and in an administrative building (second visit) by nurses wearing normal
clothes (i.e., not a medical uniform), and one could expect that the white coat effect was minimized [70].
The decreased number of hypertensive persons based on two vs. one visits (this number being
used in the denominator) resulted in increased proportions of persons aware, treated and controlled
for hypertension in the underlying population when the prevalence of hypertension was based on BP
readings taken on two vs. one visits (a relative increase of 18% in our study). We are not aware of
other studies that have explicitly quantified this difference [11]. The issue is important as it implies
that the usually low proportions of awareness, treatment and control found in many epidemiological
surveys that have assessed BP on a single visit might not be as low as they appear if the prevalence of
hypertension was assessed based on BP readings taken on several visits. Further studies on awareness,
treatment and control rates should attempt to include a more valid denominator (i.e., the number of
persons with hypertension based on two or more visits) or, at least, such studies should attempt to
explicitly discuss and quantify the possible underestimation in these awareness, treatment and control
proportions when hypertension is assessed based on BP measured on ≥two vs. one visits.
This study examined the validity of the diagnosis of hypertension when BP was measured on
two vs. one visits. However, correctly assigning hypertension diagnoses to persons who have BP
permanently ≥140/90 mmHg (or another BP cut-off) does not imply that it is inadequate to prescribe
BP-lowering treatment to selected persons with lower BP levels but high cardiovascular risk (based on
other elevated risk factors) in order to reduce their total cardiovascular risk (e.g., total risk approach,
“polypill” interventions, etc.) [71]. Nonetheless, a valid assessment of the prevalence of hypertension
(based on BP readings measured on several visits) in epidemiological surveys is important for both
surveillance and policy purposes.
Our study has several strengths. First, participants from our community-based screening
programme included adults from the general population. Although participants were not randomly
selected from the general population, the population-based nature of the sample is supported by the
fact that the prevalence of hypertension in the screening programme was similar to that found in a
national survey of BP and other risk factors in the Seychelles [67]. Second, untreated participants
with high BP in the screening programme had their BP rechecked on a second visit. With regard to
our review, no previous paper had made a systematic review of the prevalence of hypertension in
community surveys based on BP readings on two vs. one visits. Our study and narrative review
also have limitations. First, the sample of our case study was fairly small. Yet, the sample is likely
sufficiently large to indicate the approximate magnitude of the estimates under study, and our review
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of the literature concurred with our results. Second, we did not assess the validity of the hypertension
diagnosis in persons in the screening programme treated for hypertension (some of whom might not
have been hypertensive in the first place, up to one-quarter in some studies [68]). Third, we did not
assess the impact of measuring BP on more than two visits in our screening programme. Fourth, we did
not assess the impact of using different combinations of BP readings at each visit (e.g., last two of three
readings, two readings, more readings) for the sake of simplicity and because these factors may have a
marginal impact as compared to differences in BP readings taken on several visits [11]. With regard to
our narrative review, we did not attempt to meta-analyse an overall estimate of the overestimation of
hypertension based on two vs. one visits, as the included epidemiological studies have used largely
different methods (definition of hypertension, number of BP readings per visit, participants eligible for
repeat visits, mean BP level in the underlying population, etc.).
5. Conclusions
In conclusion, our community screening programme and our narrative review re-emphasize that
the prevalence of hypertension in the underlying population is markedly lower when based on BP
readings measured on two vs. one visits. From an individual-based perspective, it is sometimes argued
that defining the diagnosis of hypertension based on a single visit can still be useful to avoid suspected
hypertension cases not coming back for confirmatory measurements and/or treatment on subsequent
days. In Tanzania, less than one-third of the newly identified hypertensive persons from a large
epidemiological survey attended at least one further medical visit during the next 12 months despite
being advised to do so, and in the Seychelles, only 20% of newly discovered hypertension cases from a
national population-based survey regularly took their prescribed medication after 12 months [44,45].
Whereas a low uptake of adequate BP management for a condition that generally shows no symptoms
is unfortunate (and needs to be addressed), a valid diagnosis of hypertension is important to avoid
unnecessary worries and treatment among false-positive cases (clinical perspective), as well as for
adequate surveillance of the prevalence of hypertension and related health policy (epidemiological
perspective). The validity of hypertension prevalence estimates in epidemiological studies could be
improved by measuring BP on a second visit (or, possibly, by taking additional BP readings at a first
visit) for all persons or for a random sample of persons with elevated BP and no treatment at the
first visit [5,47] or, at least, by attempting to quantify the possible overestimation of the prevalence
of hypertension in surveys in which BP was measured on one single visit based on estimates of the
relative reduction of the prevalence of hypertension from studies that have measured BP on more than
one visit [41,72].
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